Follow Michael A Robinson Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
The S&P 500 has moved roughly 10% higher since trading began last Jan. 3. The Dow Jones Industrial Average has done even better, gaining a little more than 11.3% in the period.
And both indexes stand near their record highs.
That's not bad.
But you can do better.
A lot better.
"Fulfilling financial dreams" better.
In fact, if you followed my recommendation following our July 28 chat, you would have beat the gains of both those indexes.
In a single day.
At the time, I told you all about Arista Networks Inc. (NYSE: ANET). I ran it through the five filters of my Tech Wealth Blueprint – our system for spotting big tech winners – and came to the conclusion that Arista was a great long-term buy.
Turns out, I was wrong.
Arista was a great short-term buy, too.
Just 10 days later, the stock skyrocketed nearly 19.5% in a single session after the firm reported stellar earnings.
Today, I'm going to tell you about a small-cap stock that did even better. It made 22% one-day gains.
And you can get in on recommendations coming to you like clockwork.
Here's how…
See, if you have the right tech investing "guru" in your corner – like myself or any of the top editors here at Money Morning – you can truly crush the market.
This isn't just an idle boast. I can back it all up.
Just look at the returns members of my premium trading service Radical Technology Profits are scoring.
On Aug. 8, one of our medtech leaders soared 22% in a single day on a great earnings report. That move meant we were up more than 90% in just over seven months.
And on that very same day, we sold half of our holdings in another biotech leader for gains of roughly 105%.
Now then, "Rad Tech" focuses on aggressive, fast-growing small-cap tech firms. That means it may be too aggressive for investors just getting started.
Fortunately, I have another tech-investing service that is ideal for newer investors who want to build wealth fast – and with very little risk.
Members of this service are making enough to put aside money for their grandkids' college funds… for their own retirements… even for things like dream vacations and 40-foot yachts.
So now that we are closing the books on second-quarter earnings, let's take a look at four big Nova-X Report winners in the second quarter.
I'm listing them in ascending order…
Nova-X Market Crusher No. 4: Biotech Cloud Play Yields 25%
I just love it when the collision of two red-hot trends hands us huge gains. In May 2016, I recommended that Nova-X members buy shares of a firm that develops and markets cloud-based management for the biotech and drug sectors.
This investment couldn't have worked out better. Back on May 22, we sold half that stake for gains of roughly 108%. That "free trade" meant we got all our original capital back – and are now playing on the house's money.
We closed the June quarter with roughly 25% gains. But I still see plenty of upside ahead.
That's because the firm is now pushing its unique cloud-based document and relationship-management platform beyond its core life-sciences market. It's now making inroads into the broader industrial and manufacturing sectors.
Before that move, the company was already on track to hit $1 billion in yearly sales by 2020. Moving into new markets could double or even triple its long-term potential.
Nova-X Market Crusher No. 3: Medtech Leader Advances 26%
Most of the time, you only see big quarterly gains in smaller firms.
After all, it's much easier to bump a small-cap company's valuation by $100 million than it is to tweak a big-cap firm's value by $5 billion.
But that's how much wealth was created for investors of a medtech firm focused on heart patients – a medtech firm that members of Nova-X are benefiting from. During the quarter, the stock rallied for gains of nearly 26%.
And for good reason…
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.